Dr. Selim Ramin Benbadis, MD

Dr. Benbadis practices at Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital.

Dr. Benbadis' NPI, 1710902689, was assigned on July 13, 2006. Dr. Benbadis graduated from Other in 1987. Dr. Benbadis holds Florida license ME61493.

Dr. Benbadis' primary practice is Tampa General Hospital, at 1 Tampa General Cir, Tampa, FL 33606 in Hillsborough County. The practice phone is (813) 844-7000.

Dr. Benbadis' primary practice is Tampa General Hospital in Tampa, Florida, part of Tampa General Hospital. The medical group on file is USF Therapy Services. Dmand AI also links Dr. Benbadis to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Benbadis practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Benbadis' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Benbadis is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Benbadis' licenses on file in 6 states: Florida, Maine, Pennsylvania, Wisconsin, Ohio and Illinois.

Dmand AI lists epilepsy and seizures among the conditions Dr. Benbadis treats.

CMS data shows 536 Medicare services from Dr. Benbadis across 8 procedure codes in 2024, for 309 Medicare patients. Medicare paid $40,803 for them.

CMS counts 309 Medicare patients who saw Dr. Benbadis in 2024. The largest group is under 65, with 135 patients. 71% of them have high cholesterol, and 69% have high blood pressure. 42% are also on Medicaid. Their average risk score is 2.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Benbadis' median patient age at 51, with 53% women.

In 2024, Dr. Benbadis wrote 4,258 Medicare Part D claims for 287 patients. 71% of them were for generic drugs. CMS names the drug for 4,106 of them, across 46 drugs with 11 or more claims each, at $3,578,531 in total drug cost. In 2023, CMS named 3,558 claims across 40 drugs.

Dr. Benbadis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Benbadis as offering telehealth.

Dmand AI links 202 papers to Dr. Benbadis, published from 2006 to 2025. 2015 was the busiest year, with 9. The most frequent topics are Electroencephalography, Epilepsy and Seizures. Dr. Benbadis has published most often in Epilepsy Behav. Dr. Benbadis' most frequent co-authors are William O. Tatum, DO, Ushtar Amin, MD and Ali M. Bozorg, MD.

Dmand AI links Dr. Benbadis to 6 clinical trials, 2 of them phase 2 studies. Conditions studied include Epilepsy, Seizures and Epilepsies, Partial. Lundbeck LLC sponsors the most, 2.

CMS Open Payments shows 4,503 general payments to Dr. Benbadis from 33 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 57% of the total. Eisai Inc. paid the most, $507,224. It also lists 2 research payments totaling $2,750 from 2017 to 2018.

Dmand AI lists 9 awards for Dr. Benbadis, most recently CMS Stage 1 EHR in 2012.

Dr. Benbadis graduated from Other in 1987.

Dr. Benbadis is in network with 19 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.